Management ChangeMay 27, 2026, 04:07 PM
Zentalis Appoints Shannon Campbell to Board, Sarah Kelly as SVP Commercial
AI Summary
Zentalis Pharmaceuticals announced the appointments of Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy. These strategic hires aim to bolster the company's commercial and operational capabilities as it advances its registrational program for azenosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The company is preparing for potential commercialization, with a DENALI Phase 2 trial readout expected by year-end 2026 and a Phase 3 confirmatory trial underway.
Key Highlights
- Shannon Campbell appointed to Zentalis' Board of Directors.
- Sarah Kelly appointed Senior Vice President of Commercial Strategy.
- Appointments enhance commercialization readiness for azenosertib.
- Azenosertib is a first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer.
- Anticipated year-end 2026 topline readout from DENALI Phase 2 trial.
- First patient dosed in ASPENOVA Phase 3 confirmatory trial.
- Azenosertib holds US FDA Fast Track Designation for its indication.
Price Impact
More from ZNTL